Search
Peramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalThe development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. … Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company.
Isoniazid
go.drugbank.com/drugs/DB00951ApprovedInvestigationalAntibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Aceclidine
go.drugbank.com/drugs/DB13262Approved[A274283] As compared to less selective miotics, like [pilocarpine], aceclidine's relative stimulation of the ciliary muscle is significantly less and, as such, induces far less myopic shift, lens thickening … [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]
Crotamiton
go.drugbank.com/drugs/DB00265ApprovedCrotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor.
Toripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalIt was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … [A262011,A262591] Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.[L48696]
Zoledronic acid
go.drugbank.com/drugs/DB00399ApprovedInvestigational[L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712]
Cyproterone acetate
go.drugbank.com/drugs/DB04839ApprovedInvestigationalAn anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. … It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
Grepafloxacin
go.drugbank.com/drugs/DB00365ApprovedWithdrawnDue to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States
Deferoxamine
go.drugbank.com/drugs/DB00746ApprovedInvestigationalIt forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalOn May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia